SCHEMBL26324657

SCHEMBL26324657

CCOCCCNC(=O)c1ccc(/N=N/c2cc(CCNC)ccc2O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
KMT2A Q03164 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 1/20 0.44
NAMPT P43490 2/20 0.42
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
NME4 O00746 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
ADORA2A P29274 1/20 0.40
AVPR2 P30518 1/20 0.40
AGTR1 P30556 1/20 0.40
SLC6A4 P31645 1/20 0.40
AVPR1A P37288 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24346426 0.85 HTT (0.46) HPGDRAB9ASMN1; SMN2KMT2AL3MBTL1
SCHEMBL23015946 0.83 ESRRG (0.37) RAB9ANPC1SMN1; SMN2KMT2AHTT
SCHEMBL21307589 0.80 ESRRG (0.36) SMN1; SMN2L3MBTL1HTTMAPTTP53
SCHEMBL21307471 0.80 ESRRG (0.35) SMN1; SMN2L3MBTL1HTTNME4ADORA3
SCHEMBL21307568 0.80 HTT (0.38) HPGDRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL23015947 0.80 HPGD (0.38) HPGDRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL21307569 0.79 MAP4K1 (0.35) RAB9ANPC1KMT2AHTTMEN1
SCHEMBL17320175 0.79 CA1 (0.52) HPGDRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL21307560 0.78 ESRRG (0.40) HPGDRAB9ANPC1HTTNME4
SCHEMBL23561922 0.78 ESRRG (0.35) HPGDSMN1; SMN2KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767298-B2 Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase DUKE UNIVERSITY (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767298-B2 Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase TAB1, CHUK, TGFBR1 HPGD 3093/4885RAB9A 3987/4885NPC1 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.